These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
378 related articles for article (PubMed ID: 30199472)
1. Baseline risk assessment of patients with ulcerative colitis: does initial treatment selection influence outcomes? Mosli M; Alfaer S; Almalaki T; Albeshry A; Aljehani S; Alshmrani B; Habib Z; Jawa H; Qari Y Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):80-85. PubMed ID: 30199472 [TBL] [Abstract][Full Text] [Related]
2. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients. Chaparro M; Barreiro-de Acosta M; Echarri A; Almendros R; Barrio J; Llao J; Gomollón F; Vera M; Cabriada JL; Guardiola J; Guerra I; Beltrán B; Roncero O; Busquets D; Taxonera C; Calvet X; Ferreiro-Iglesias R; Ollero Pena V; Bernardo D; Donday MG; Garre A; Godino A; Díaz A; Gisbert JP Dig Dis Sci; 2019 Mar; 64(3):846-854. PubMed ID: 30426297 [TBL] [Abstract][Full Text] [Related]
3. Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study. Barberio B; Zingone F; D'Incà R; Rovigo L; Bertani L; Bodini G; Ghisa M; Gubbiotti A; Massimi D; Lorenzon G; Savarino EV Clin Transl Gastroenterol; 2020 May; 11(5):e00177. PubMed ID: 32677808 [TBL] [Abstract][Full Text] [Related]
4. Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study. Bosca-Watts MM; Cortes X; Iborra M; Huguet JM; Sempere L; Garcia G; Gil R; Garcia M; Muñoz M; Almela P; Maroto N; Paredes JM World J Gastroenterol; 2016 Dec; 22(47):10432-10439. PubMed ID: 28058024 [TBL] [Abstract][Full Text] [Related]
5. Predictors of Thiopurine Treatment Failure in Biologic-Naïve Ulcerative Colitis Patients. Thapa SD; Hadid H; Usman M; Imam W; Hassan A; Schairer J; Jafri SM; Kaur N Dig Dis Sci; 2016 Jan; 61(1):230-7. PubMed ID: 26511478 [TBL] [Abstract][Full Text] [Related]
6. Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study. Ma C; Beilman CL; Huang VW; Fedorak DK; Wong K; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN Can J Gastroenterol Hepatol; 2016; 2016():2079582. PubMed ID: 27478817 [TBL] [Abstract][Full Text] [Related]
7. Ultrastructural evidence of mucosal healing after infliximab in patients with ulcerative colitis. Fratila OC; Craciun C J Gastrointestin Liver Dis; 2010 Jun; 19(2):147-53. PubMed ID: 20593047 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients. Iborra M; Pérez-Gisbert J; Bosca-Watts MM; López-García A; García-Sánchez V; López-Sanromán A; Hinojosa E; Márquez L; García-López S; Chaparro M; Aceituno M; Calafat M; Guardiola J; Belloc B; Ber Y; Bujanda L; Beltrán B; Rodríguez-Gutiérrez C; Barrio J; Cabriada JL; Rivero M; Camargo R; van Domselaar M; Villoria A; Schuterman HS; Hervás D; Nos P; J Gastroenterol; 2017 Jul; 52(7):788-799. PubMed ID: 27722996 [TBL] [Abstract][Full Text] [Related]
9. Rectal sparing and skip lesions in ulcerative colitis: a comparative study of endoscopic and histologic findings in patients who underwent proctocolectomy. Joo M; Odze RD Am J Surg Pathol; 2010 May; 34(5):689-96. PubMed ID: 20410806 [TBL] [Abstract][Full Text] [Related]
10. Repeated intensified infliximab induction - results from an 11-year prospective study of ulcerative colitis using a novel treatment algorithm. Johnsen KM; Goll R; Hansen V; Olsen T; Rismo R; Heitmann R; Gundersen MD; Kvamme JM; Paulssen EJ; Kileng H; Johnsen K; Florholmen J Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):98-104. PubMed ID: 27749779 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of the Risk of Relapse in Ulcerative Colitis According to the Degree of Mucosal Healing (Mayo 0 vs 1): A Longitudinal Cohort Study. Barreiro-de Acosta M; Vallejo N; de la Iglesia D; Uribarri L; Bastón I; Ferreiro-Iglesias R; Lorenzo A; Domínguez-Muñoz JE J Crohns Colitis; 2016 Jan; 10(1):13-9. PubMed ID: 26351390 [TBL] [Abstract][Full Text] [Related]
12. Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis. Baki E; Zwickel P; Zawierucha A; Ehehalt R; Gotthardt D; Stremmel W; Gauss A World J Gastroenterol; 2015 Mar; 21(11):3282-90. PubMed ID: 25805935 [TBL] [Abstract][Full Text] [Related]
13. Comparison of health-related quality of life and disability in ulcerative colitis patients following restorative proctocolectomy with ileal pouch-anal anastomosis versus anti-tumor necrosis factor therapy. van Gennep S; Sahami S; Buskens CJ; van den Brink GR; Ponsioen CY; D'Hoore A; de Buck van Overstraeten A; van Assche G; Ferrante M; Vermeire S; Bemelman WA; D'Haens GR; Löwenberg M Eur J Gastroenterol Hepatol; 2017 Mar; 29(3):338-344. PubMed ID: 27902515 [TBL] [Abstract][Full Text] [Related]
14. Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative Colitis. Telesco SE; Brodmerkel C; Zhang H; Kim LL; Johanns J; Mazumder A; Li K; Baribaud F; Curran M; Strauss R; Paxson B; Plevy S; Davison T; Knight L; Dibben S; Schreiber S; Sandborn W; Rutgeerts P; Siegel CA; Reinisch W; Greenbaum LE Gastroenterology; 2018 Oct; 155(4):1008-1011.e8. PubMed ID: 29981298 [TBL] [Abstract][Full Text] [Related]
15. Long-term assessment of clinical response to adalimumab therapy in refractory ulcerative colitis. Hussey M; Mc Garrigle R; Kennedy U; Holleran G; Kevans D; Ryan B; Breslin N; Mahmud N; McNamara D Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):217-21. PubMed ID: 26587866 [TBL] [Abstract][Full Text] [Related]
16. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Colombel JF; Rutgeerts P; Reinisch W; Esser D; Wang Y; Lang Y; Marano CW; Strauss R; Oddens BJ; Feagan BG; Hanauer SB; Lichtenstein GR; Present D; Sands BE; Sandborn WJ Gastroenterology; 2011 Oct; 141(4):1194-201. PubMed ID: 21723220 [TBL] [Abstract][Full Text] [Related]
17. Infliximab is superior to other biological agents for treatment of active ulcerative colitis: A meta-analysis. Mei WQ; Hu HZ; Liu Y; Li ZC; Wang WG World J Gastroenterol; 2015 May; 21(19):6044-51. PubMed ID: 26019471 [TBL] [Abstract][Full Text] [Related]
18. Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up. Bryant RV; Burger DC; Delo J; Walsh AJ; Thomas S; von Herbay A; Buchel OC; White L; Brain O; Keshav S; Warren BF; Travis SP Gut; 2016 Mar; 65(3):408-14. PubMed ID: 25986946 [TBL] [Abstract][Full Text] [Related]
19. Risk Stratification of Patients with Crohn's Disease: A Retrospective Analysis of Clinical Decision Making and Its Impact on Long-Term Outcome. Mosli M; Sabbahi H; Alyousef H; Abdulhaq M; Hadadi A; Aljahdali E; Jawa H; Bazarah S; Qari Y Dig Dis; 2018; 36(1):49-55. PubMed ID: 28654928 [TBL] [Abstract][Full Text] [Related]
20. Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy. Subramaniam K; Richardson A; Dodd J; Platten J; Shadbolt B; Pavli P Intern Med J; 2014 May; 44(5):464-70. PubMed ID: 24612209 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]